Flavonoids and Drug Interactions

Flavonoid Pharmacokinetics: Methods of Analysis, Preclinical and Clinical Pharmacokinetics, Safety, and Toxicology

Volumn , Issue , 2012, Pages 281-319

  Yáñez, Jaime A ^a   Chemuturi, Nagendra V ^a   Womble, Scott W ^a   Sayre, Casey L ^b   Davies, Neal M ^b  

^a ALCON RESEARCH LTD   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Flavonoid ABC transporter, ATP hydrolysis modulation; Flavonoid drug interactions by food beverage herbal intake; Flavonoid drug, modulation in concentration dependent manner; Flavonoids and drug interactions; Multidrug resistance protein 2 (MRP2, ABCC2)

Indexed keywords

EID: 84887165255     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118468524.ch7     Document Type: Chapter

References (242)

1. Scalbert, A., Johnson, I.T., Saltmarsh, M. (2005). Polyphenols: Antioxidants and beyond. The American Journal of Clinical Nutrition 81(Suppl. 1):215S-217S.
2. Fremont, L. (2000). Biological effects of resveratrol. Life Sciences 66(8):663-673.
3. R imando, A.M., et al. (2002). Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. Journal of Agricultural and Food Chemistry 50(12):3453-3457.
4. R oupe, K., et al. (2006). Pharmacometrics of stilbenes: Seguing towards the clinic. Current Clinical Pharmacology 1(1):81-101.
5. Haslam, E. (1998). Practical Polyphenolics: From Structure to Molecular Recognition and Physiological Action. Cambridge, UK: Cambridge University Press.
6. C ook, N.C., Samman, S. (1996). Flavonoids-Chemistry, metabolism, cardioprotective effects, and dietary sources. The Journal of Nutritional Biochemistry 6:66-76.
7. Alvarez, A.I., et al. (2010). Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. Journal of Pharmaceutical Sciences 99(2):598-617.
8. Manach, C., et al. (2004). Polyphenols: Food sources and bioavailability. The American Journal of Clinical Nutrition 79(5):727-747.
9. Piskula, M.K., Terao, J. (1998). Accumulation of (-)-epicatechin metabolites in rat plasma after oral administration and distribution of conjugation enzymes in rat tissues. The Journal of Nutrition 128(7):1172-1178.
10. Spencer, J.P., et al. (1999). The small intestine can both absorb and glucuronidate luminal flavonoids. FEBS Letters 458(2):224-230.
11. C respy, V., et al. (2001). Comparison of the intestinal absorption of quercetin, phloretin and their glucosides in rats. The Journal of Nutrition 131(8):2109-2114.
12. Boersma, M.G., et al. (2002). Regioselectivity of phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases. Chemical Research in Toxicology 15(5):662-670.
13. Spencer, J.P., Abd-El-Mohsen, M.M., Rice-Evans, C. (2004). Cellular uptake and metabolism of flavonoids and their metabolites: Implications for their bioactivity. Archives of Biochemistry and Biophysics 423(1):148-161.
14. Heim, K.E., Tagliaferro, A.R., Bobilya, D.J. (2002). Flavonoid antioxidants: Chemistry, metabolism and structure-activity relationships. The Journal of Nutritional Biochemistry 13(10):572-584.
15. Zhang, L., Zuo, Z., Lin, G. (2007). Intestinal and hepatic glucuronidation of flavonoids. Molecular Pharmacology 4(6):833-845.
16. Walle, T., et al. (2001). Disposition and metabolism of the flavonoid chrysin in normal volunteers. British Journal of Clinical Pharmacology 51(2):143-146.
17. Setchell, K.D., et al. (2001). Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. The Journal of Nutrition 131(Suppl. 4):1362S-1375S.
18. Tukey, R.H., Strassburg, C.P. (2000). Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. Annual Review of Pharmacology and Toxicology 40:581-616.
19. K aminsky, L.S., Zhang, Q.Y. (2003). The small intestine as a xenobiotic-metabolizing organ. Drug Metabolism and Disposition: The Biological Fate of Chemicals 31(12):1520-1525.
20. R imbach, G., et al. (2004). Sulfation of genistein alters its antioxidant properties and its effect on platelet aggregation and monocyte and endothelial function. Biochimica et Biophysica Acta 1670(3):229-237.
21. Donnini, S., et al. (2006). Divergent effects of quercetin conjugates on angiogenesis. The British Journal of Nutrition 95(5):1016-1023.
22. Tribolo, S., et al. (2008). Comparative effects of quercetin and its predominant human metabolites on adhesion molecule expression in activated human vascular endothelial cells. Atherosclerosis 197(1):50-56.
23. Yang, J.H., et al. (2006). Inhibition of lung cancer cell growth by quercetin glucuronides via G2/M arrest and induction of apoptosis. Drug Metabolism and Disposition: The Biological Fate of Chemicals 34(2):296-304.
24. Harada, M., et al. (1999). Identification of the major antioxidative metabolites in biological fluids of the rat with ingested (+)-catechin and (-)-epicatechin. Bioscience, Biotechnology, and Biochemistry 63(6):973-977.
25. Terao, J., et al. (2001). Protection by quercetin and quercetin 3-O-beta-D-glucuronide of peroxynitrite-induced antioxidant consumption in human plasma lowdensity lipoprotein. Free Radical Research 35(6):925-931.
26. L ambert, J.D., Sang, S., Yang, C.S. (2007). Biotransformation of green tea polyphenols and the biological activities of those metabolites. Molecular Pharmacology 4(6):819-825.
27. Setchell, K.D., Brown, N.M., Lydeking-Olsen, E. (2002). The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. The Journal of Nutrition 132(12):3577-3584.
28. L und, T.D., et al. (2004). Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. Biology of Reproduction 70(4):1188-1195.
29. Di Virgilio, A.L., et al. (2004). Genotoxicity of the isoflavones genistein, daidzein and equol in V79 cells. Toxicology Letters 151(1):151-162.
30. C lere, N., et al. (2011). Anticancer properties of flavonoids: Roles in various stages of carcinogenesis. Cardiovascular & Hematological Agents in Medicinal Chemistry 9(2):62-77.
31. L oguercio, C., Festi, D. (2011). Silybin and the liver: From basic research to clinical practice. World Journal of Gastroenterology 17(18):2288-2301.
32. Dresser, G.K., Bailey, D.G. (2003). The effects of fruit juices on drug disposition: A new model for drug interactions. European Journal of Clinical Investigation 33(Suppl. 2):10-16.
33. Ofer, M., et al. (2005). Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT. European Journal of Pharmaceutical Sciences 25(2-3):263-271.
34. Obach, R.S. (2000). Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. The Journal of Pharmacology and Experimental Therapeutics 294(1):88-95.
35. Ding, X., Kaminsky, L.S. (2003). Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annual Review of Pharmacology and Toxicology 43:149-173.
36. R oberts-Kirchhoff, E.S., et al. (1999). Metabolism of genistein by rat and human cytochrome P450s. Chemical Research in Toxicology 12(7):610-616.
37. Eisenberg, D.M., et al. (1998). Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 280(18): 1569-1575.
38. R obertson, S.M., et al. (2008). Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Current Medical Research and Opinion 24(2):591-599.
39. Hebert, M.F., et al. (2004). Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. Journal of Clinical Pharmacology 44(1):89-94.
40. Ahmed, S.M., Banner, N.R., Dubrey, S.W. (2001). Low cyclosporin-A level due to Saint-John's-wort in heart transplant patients. The Journal of Heart and Lung Transplantation 20(7):795.
41. K arliova, M., et al. (2000). Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. Journal of Hepatology 33(5):853-855.
42. Barone, G.W., et al. (2001). Herbal supplements: A potential for drug interactions in transplant recipients. Transplantation 71(2):239-241.
43. Durr, D., et al. (2000). St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clinical Pharmacology and Therapeutics 68(6): 598-604.
44. C apasso, R., et al. (2008). Inhibitory effect of the herbal antidepressant St. John's wort (Hypericum perforatum) on rat gastric motility. Naunyn-Schmiedeberg's Archives of Pharmacology 376(6):407-414.
45. Fan, L., et al. (2009). Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica 39(3):249-254.
46. Yin, O.Q., et al. (2004). Pharmacogenetics and herb-drug interactions: Experience with Ginkgo biloba and omeprazole. Pharmacogenetics 14(12):841-850.
47. Bailey, D.G., et al. (1998). Grapefruit juice-drug interactions. British Journal of Clinical Pharmacology 46(2):101-110.
48. Fuhr, U. (1998). Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Safety 18(4):251-272.
49. Mertens-Talcott, S.U., et al. (2006). Grapefruit-drug interactions: Can interactions with drugs be avoided. Journal of Clinical Pharmacology 46(12):1390-1416.
50. Seden, K., et al. (2010). Grapefruit-drug interactions. Drugs 70(18):2373-2407.
51. Brand, W., et al. (2006). Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomedicine and Pharmacotherapy 60(9):508-519.
52. Dresser, G.K., et al. (2002). Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clinical Pharmacology and Therapeutics 71(1):11-20.
53. C vetkovic, M., et al. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metabolism and Disposition: The Biological Fate of Chemicals 27(8):866-871.
54. Bailey, D.G., et al. (2000). Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients. Clinical Pharmacology and Therapeutics 68(5):468-477.
55. Ducharme, M.P., Warbasse, L.H., Edwards, D.J. (1995). Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clinical Pharmacology and Therapeutics 57(5):485-491.
56. K oitabashi, Y., et al. (2006). Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects. Life Sciences 78(24):2852-2859.
57. R oth, M., Timmermann, B.N., Hagenbuch, B. (2011). Interactions of green tea catechins with organic anion-transporting polypeptides. Drug Metabolism and Disposition: The Biological Fate of Chemicals 39(5):920-926.
58. Berginc, K., Trontelj, J., Kristl, A. (2010). The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices. Drug Metabolism and Pharmacokinetics 25(3):307-313.
59. Bailey, D.G., et al. (1993). Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clinical Pharmacology and Therapeutics 54(6):589-594.
60. R ashid, J., et al. (1993). Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. British Journal of Clinical Pharmacology 36(5):460-463.
61. Hemaiswarya, S., Kruthiventi, A.K., Doble, M. (2008). Synergism between natural products and antibiotics against infectious diseases. Phytomedicine 15(8): 639-652.
62. L iu, R.H. (2004). Potential synergy of phytochemicals in cancer prevention: Mechanism of action. The Journal of Nutrition 134(Suppl. 12):3479S-3485S.
63. Ameer, B., Weintraub, R.A. (1997). Drug interactions with grapefruit juice. Clinical Pharmacokinetics 33(2):103-121.
64. V ernet, A., Siess, M.H. (1986). Comparison of the effects of various flavonoids on ethoxycoumarin deethylase activity of rat intestinal and hepatic microsomes. Food and Chemical Toxicology 24(8):857-861.
65. K rishnamurthy, P., Schuetz, J.D. (2006). Role of ABCG2/BCRP in biology and medicine. Annual Review of Pharmacology and Toxicology 46:381-410.
66. C han, L.M., Lowes, S., Hirst, B.H. (2004). The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. European Journal of Pharmaceutical Sciences 21(1):25-51.
67. Polgar, O., Robey, R.W., Bates, S.E. (2008). ABCG2: Structure, function and role in drug response. Expert Opinion on Drug Metabolism & Toxicology 4(1): 1-15.
68. Szakacs, G., et al. (2008). The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discovery Today 13(9-10):379-393.
69. van Zanden, J.J., et al. (2005). Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochemical Pharmacology 69(4):699-708.
70. Wu, C.P., et al. (2005). Modulatory effects of plant phenols on human multidrugresistance proteins 1, 4 and 5 (ABCC1, 4 and 5). The FEBS Journal 272(18): 4725-4740.
71. Wesolowska, O., et al. (2007). Influence of silybin on biophysical properties of phospholipid bilayers. Acta Pharmacologica Sinica 28(2):296-306.
72. van Zanden, J.J., et al. (2007). The effect of quercetin phase II metabolism on its MRP1 and MRP2 inhibiting potential. Biochemical Pharmacology 74(2): 345-351.
73. Zhang, L., et al. (2007). Mechanistic study on the intestinal absorption and disposition of baicalein. European Journal of Pharmaceutical Sciences 31(3-4):221-231.
74. Trompier, D., et al. (2003). Multiple flavonoid-binding sites within multidrug resistance protein MRP1. Cellular and Molecular Life Sciences 60(10):2164-2177.
75. L eslie, E.M., et al. (2001). Modulation of multidrug resistance protein 1 (MRP1/ ABCC1) transport and atpase activities by interaction with dietary flavonoids. Molecular Pharmacology 59(5):1171-1180.
76. Perez-Victoria, J.M., et al. (1999). Correlation between the affinity of flavonoids binding to the cytosolic site of Leishmania tropica multidrug transporter and their efficiency to revert parasite resistance to daunomycin. Biochemistry 38(6): 1736-1743.
77. Perez-Victoria, J.M., et al. (2002). Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: A search for reversal agents. Current Drug Targets 3(4):311-333.
78. C onseil, G., et al. (2000). Prenyl-flavonoids as potent inhibitors of the Pdr5p multidrug ABC transporter from Saccharomyces cerevisiae. Biochemistry 39(23): 6910-6917.
79. Aszalos, A. (2008). Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs. Current Drug Metabolism 9(10): 1010-1018.
80. Morris, M.E., Zhang, S. (2006). Flavonoid-drug interactions: Effects of flavonoids on ABC transporters. Life Sciences 78(18):2116-2130.
81. van de Wetering, K., et al. (2009). Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Molecular Pharmacology 75(4):876-885.
82. Tamura, A., et al. (2007). In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Drug Metabolism and Pharmacokinetics 22(6):428-440.
83. Di Pietro, A., et al. (1999). P-glycoprotein-mediated resistance to chemotherapy in cancer cells: Using recombinant cytosolic domains to establish structurefunction relationships. Brazilian Journal of Medical and Biological Research 32(8):925-939.
84. Boumendjel, A., et al. (2005). Anticancer multidrug resistance mediated by MRP1: Recent advances in the discovery of reversal agents. Medicinal Research Reviews 25(4):453-472.
85. DuBuske, L.M. (2005). The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Safety 28(9):789-801.
86. R obey, R.W., et al. (2009). ABCG2: A perspective. Advanced Drug Delivery Reviews 61(1):3-13.
87. Zhang, L., et al. (2008). A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38(7-8):709-724.
88. Zhang, L., et al. (2010). Drug interactions evaluation: An integrated part of risk assessment of therapeutics. Toxicology and Applied Pharmacology 243(2): 134-145.
89. Pulido, M.M., et al. (2006). Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): Influence of flavonoids and role in milk secretion in sheep. Journal of Veterinary Pharmacology and Therapeutics 29(4): 279-287.
90. C ao, J., et al. (2007). Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra. Drug Metabolism and Disposition: The Biological Fate of Chemicals 35(4):539-553.
91. Wang, Y., Cao, J., Zeng, S. (2005). Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: Quercetin, kaempferol, and isorhamnetin. The Journal of Pharmacy and Pharmacology 57(6):751-758.
92. C ermak, R., Wolffram, S. (2006). The potential of flavonoids to influence drug metabolism and pharmacokinetics by local gastrointestinal mechanisms. Current Drug Metabolism 7(7):729-744.
93. Walle, U.K., et al. (1999). Transport of genistein-7-glucoside by human intestinal CACO-2 cells: Potential role for MRP2. Research Communications in Molecular Pathology and Pharmacology 103(1):45-56.
94. Walle, U.K., Galijatovic, A., Walle, T. (1999). Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochemical Pharmacology 58(3):431-438.
95. Walgren, R.A., et al. (2000). Efflux of dietary flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistanceassociated protein-2. The Journal of Pharmacology and Experimental Therapeutics 294(3):830-836.
96. Juergenliemk, G., et al. (2003). In vitro studies indicate that miquelianin (quercetin 3-O-beta-D-glucuronopyranoside) is able to reach the CNS from the small intestine. Planta Medica 69(11):1013-1017.
97. Hu, M., Chen, J., Lin, H. (2003). Metabolism of flavonoids via enteric recycling: Mechanistic studies of disposition of apigenin in the Caco-2 cell culture model. The Journal of Pharmacology and Experimental Therapeutics 307(1): 314-321.
98. V aidyanathan, J.B., Walle, T. (2001). Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharmaceutical Research 18(10):1420-1425.
99. K aldas, M.I., Walle, U.K., Walle, T. (2003). Resveratrol transport and metabolism by human intestinal Caco-2 cells. The Journal of Pharmacy and Pharmacology 55(3):307-312.
100. Maier-Salamon, A., et al. (2008). Metabolism and disposition of resveratrol in the isolated perfused rat liver: Role of Mrp2 in the biliary excretion of glucuronides. Journal of Pharmaceutical Sciences 97(4):1615-1628.
101. C ao, F., et al. (2008). Mrp2-related efflux of scutellarin in the intestinal absorption in rats. Die Pharmazie 63(1):75-80.
102. R obey, R.W., et al. (2001). Overexpression of the ATP-binding cassette halftransporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clinical Cancer Research 7(1):145-152.
103. Imai, Y., et al. (2004). Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Research 64(12):4346- 4352.
104. Enokizono, J., Kusuhara, H., Sugiyama, Y. (2007). Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Molecular Pharmacology 72(4):967-975.
105. Youdim, K.A., et al. (2004). Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radical Biology and Medicine 36(5):592-604.
106. Sesink, A.L., et al. (2005). Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Molecular Pharmacology 67(6):1999-2006.
107. Hegedus, C., et al. (2009). Ins and outs of the ABCG2 multidrug transporter: An update on in vitro functional assays. Advanced Drug Delivery Reviews 61(1): 47-56.
108. Saito, H., et al. (2006). A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. The Journal of Pharmacology and Experimental Therapeutics 317(3):1114-1124.
109. Schlatter, P., Gutmann, H., Drewe, J. (2006). Primary porcine proximal tubular cells as a model for transepithelial drug transport in human kidney. European Journal of Pharmaceutical Sciences 28(1-2):141-154.
110. van Breemen, R.B., Li, Y. (2005). Caco-2 cell permeability assays to measure drug absorption. Expert Opinion on Drug Metabolism & Toxicology 1(2):175-185.
111. Xia, C.Q., et al. (2005). Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metabolism and Disposition: The Biological Fate of Chemicals 33(5):637-643.
112. Siissalo, S., et al. (2007). Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines. European Journal of Pharmaceutics and Biopharmaceutics 67(2):548-554.
113. Berginc, K., Kristl, A. (2011). Transwell-grown HepG2 cell monolayers as in vitro permeability model to study drug-drug or drug-food interactions. Journal of Medicinal Food 14(1-2):135-139.
114. U wai, Y., et al. (2011). Inhibitory effect of caffeic acid on human organic anion transporters hOAT1 and hOAT3: A novel candidate for food-drug interaction. Drug Metabolism and Pharmacokinetics 26(5):486-493.
115. Zhou, S., Lim, L.Y., Chowbay, B. (2004). Herbal modulation of P-glycoprotein. Drug Metabolism Reviews 36(1):57-104.
116. C onseil, G., et al. (1998). Flavonoids: A class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proceedings of the National Academy of Sciences of the United States of America 95(17):9831-9836.
117. Wang, E.J., Barecki-Roach, M., Johnson, W.W. (2002). Elevation of P-glycoprotein function by a catechin in green tea. Biochemical and Biophysical Research Communications 297(2):412-418.
118. Mitsunaga, Y., et al. (2000). Effect of bioflavonoids on vincristine transport across blood-brain barrier. European Journal of Pharmacology 395(3):193-201.
119. Shapiro, A.B., Ling, V. (1997). Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. European Journal of Biochemistry 250(1):130-137.
120. Di Pietro, A., et al. (2002). Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cellular and Molecular Life Sciences 59(2):307-322.
121. Patel, J., et al. (2004). In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: Changes in P-gp and CYP3A4 activity. American Journal of Therapeutics 11(4):262-277.
122. Yoo, H.H., et al. (2007). Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. Journal of Agricultural and Food Chemistry 55(18):7620-7625.
123. Takanaga, H., et al. (1998). Inhibition of vinblastine efflux mediated by Pglycoprotein by grapefruit juice components in caco-2 cells. Biological and Pharmaceutical Bulletin 21(10):1062-1066.
124. Ikegawa, T., et al. (2000). Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Letters 160(1):21-28.
125. Takanaga, H., et al. (2000). Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. The Journal of Pharmacology and Experimental Therapeutics 293(1):230-236.
126. Ohtani, H., et al. (2007). Effects of various methoxyflavones on vincristine uptake and multidrug resistance to vincristine in P-gp-overexpressing K562/ADM cells. Pharmaceutical Research 24(10):1936-1943.
127. Wesolowska, O., et al. (2010). 8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1. European Journal of Pharmacology 644(1-3):32-40.
128. Tran, V.H., et al. (2011). Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions. Nutrition and Cancer 63(3):435-443.
129. Wang, Y.H., et al. (2005). An in silico approach for screening flavonoids as P-glycoprotein inhibitors based on a Bayesian-regularized neural network. Journal of Computer-Aided Molecular Design 19(3):137-147.
130. K othandan, G., et al. (2011). Docking and 3D-QSAR (quantitative structure activity relationship) studies of flavones, the potent inhibitors of p-glycoprotein targeting the nucleotide binding domain. European Journal of Medicinal Chemistry 46(9):4078-4088.
131. C hristians, U., Schmitz, V., Haschke, M. (2005). Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opinion on Drug Metabolism & Toxicology 1(4):641-654.
132. Evans, A.M. (2000). Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Therapeutic Drug Monitoring 22(1):131-136.
133. Ioannides, C. (2002). Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 32(6):451-478.
134. Sergent, T., et al. (2008). Molecular and cellular effects of food contaminants and secondary plant components and their plausible interactions at the intestinal level. Food and Chemical Toxicology 46(3):813-841.
135. Moon, Y.J., Wang, X., Morris, M.E. (2006). Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. Toxicology in Vitro 20(2):187-210.
136. L i, P., et al. (2007). Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction. Drug Metabolism and Disposition: The Biological Fate of Chemicals 35(7):1203-1208.
137. Wacher, V.J., Wu, C.Y., Benet, L.Z. (1995). Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Molecular Carcinogenesis 13(3):129-134.
138. Zhang, Y., Benet, L.Z. (2001). The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clinical Pharmacokinetics 40(3):159-168.
139. C ummins, C.L., et al. (2004). CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: Studies with sirolimus and midazolam. The Journal of Pharmacology and Experimental Therapeutics 308(1):143-155.
140. Zhang, Q.Y., et al. (1999). Characterization of human small intestinal cytochromes P-450. Drug Metabolism and Disposition: The Biological Fate of Chemicals 27(7):804-809.
141. Mouly, S., Paine, M.F. (2003). P-glycoprotein increases from proximal to distal regions of human small intestine. Pharmaceutical Research 20(10):1595-1599.
142. K im, D.H., et al. (1998). Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Archives of Pharmacal Research 21(1): 17-23.
143. de Castro, W.V., et al. (2007). Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. Journal of Pharmaceutical Sciences 96(10):2808- 2817.
144. de Castro, W.V., et al. (2008). Effect of grapefruit juice, naringin, naringenin, and bergamottin on the intestinal carrier-mediated transport of talinolol in rats. Journal of Agricultural and Food Chemistry 56(12):4840-4845.
145. Eagling, V.A., Profit, L., Back, D.J. (1999). Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. British Journal of Clinical Pharmacology 48(4):543-552.
146. C hoi, J.S., Shin, S.C. (2005). Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. International Journal of Pharmaceutics 292(1-2):149-156.
147. C hoi, J.S., Han, H.K. (2005). Enhanced oral exposure of diltiazem by the concomitant use of naringin in rats. International Journal of Pharmaceutics 305(1-2): 122-128.
148. Zhang, S., Morris, M.E. (2003). Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. The Journal of Pharmacology and Experimental Therapeutics 304(3):1258-1267.
149. Peng, S.X., et al. (2006). Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. Journal of Pharmaceutical Sciences 95(9):1984-1993.
150. Fromm, M.F., et al. (1999). Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [see comments]. Circulation 99(4):552-557.
151. V erschraagen, M., et al. (1999). P-glycoprotein system as a determinant of drug interactions: The case of digoxin-verapamil. Pharmacological Research 40(4): 301-306.
152. C astro, A.F., Altenberg, G.A. (1997). Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochemical Pharmacology 53(1):89-93.
153. L imtrakul, P., Khantamat, O., Pintha, K. (2005). Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. Journal of Chemotherapy (Florence, Italy) 17(1):86-95.
154. L i, X., Choi, J.S. (2007). Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats. International Journal of Pharmaceutics 337(1-2):188-193.
155. Hsiu, S.L., et al. (2002). Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sciences 72(3):227-235.
156. Borska, S., et al. (2010). Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules (Basel, Switzerland) 15(2):857-870.
157. C hoi, J.S., Han, H.K. (2004). The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits. The Journal of Pharmacy and Pharmacology 56(12):1537-1542.
158. C hoi, J.S., Choi, H.K., Shin, S.C. (2004). Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. International Journal of Pharmaceutics 275(1-2):165-170.
159. Wang, Y.H., et al. (2004). Lethal quercetin-digoxin interaction in pigs. Life Sciences 74(10):1191-1197.
160. Hodek, P., Trefil, P., Stiborova, M. (2002). Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chemico-Biological Interactions 139(1):1-21.
161. C hoi, B.C., Choi, J.S., Han, H.K. (2006). Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. International Journal of Pharmaceutics 323(1-2):81-85.
162. C hoi, J.S., Han, H.K. (2005). Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats. Pharmacological Research 52(5):386-391.
163. L i, X., Yun, J.K., Choi, J.S. (2007). Effects of morin on the pharmacokinetics of etoposide in rats. Biopharmaceutics and Drug Disposition 28(3):151-156.
164. Williamson, G., et al. (2007). Interaction of positional isomers of quercetin glucuronides with the transporter ABCC2 (cMOAT, MRP2). Drug Metabolism and Disposition: The Biological Fate of Chemicals 35(8):1262-1268.
165. Zelcer, N., et al. (2003). Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). The Journal of Biological Chemistry 278(26):23538-23544.
166. Jager, W., et al. (1997). Modulation of liver canalicular transport processes by the tyrosine-kinase inhibitor genistein: Implications of genistein metabolism in the rat. Hepatology (Baltimore, Md.) 26(6):1467-1476.
167. Sergent, T., et al. (2005). Differential modulation of ochratoxin A absorption across Caco-2 cells by dietary polyphenols, used at realistic intestinal concentrations. Toxicology Letters 159(1):60-70.
168. Schrickx, J., Lektarau, Y., Fink-Gremmels, J. (2006). Ochratoxin A secretion by ATP-dependent membrane transporters in Caco-2 cells. Archives of Toxicology 80(5):243-249.
169. K im, J.H., Chen, C., Tony Kong, A.N. (2011). Resveratrol inhibits genistein-induced multi-drug resistance protein 2 (MRP2) expression in HepG2 cells. Archives of Biochemistry and Biophysics 512(2):160-166.
170. Zhang, S., Yang, X., Morris, M.E. (2004). Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharmaceutical Research 21(7):1263-1273.
171. Zhang, S., et al. (2005). Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochemical Pharmacology 70(4):627-639.
172. Ahmed-Belkacem, A., et al. (2005). Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Research 65(11):4852-4860.
173. Takahata, T., et al. (2008). Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines. Basic & Clinical Pharmacology & Toxicology 102(4):399-407.
174. C ooray, H.C., et al. (2004). Interaction of the breast cancer resistance protein with plant polyphenols. Biochemical and Biophysical Research Communications 317(1): 269-275.
175. Zhang, S., et al. (2005). Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metabolism and Disposition: The Biological Fate of Chemicals 33(3):341-348.
176. Wang, X., Morris, M.E. (2007). Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: Potential involvement of ABCG2. Drug Metabolism and Disposition: The Biological Fate of Chemicals 35(2):268-274.
177. Schumacher, M., et al. (2010). Chrysin blocks topotecan-induced apoptosis in Caco-2 cells in spite of inhibition of ABC-transporters. Biochemical Pharmacology 80(4):471-479.
178. Wang, X., Morris, M.E. (2008). Pharmacokinetics and bioavailability of the flavonoid 7,8-benzoflavone in rats. Journal of Pharmaceutical Sciences 97(10):4546- 4556.
179. C lark, R., Kerr, I.D., Callaghan, R. (2006). Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. British Journal of Pharmacology 149(5):506-515.
180. Merino, G., et al. (2010). In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: A comparative study in Bcrp1 (-/-) mice. Pharmaceutical Research 27(10):2098-2105.
181. Brand, W., et al. (2008). Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers. Drug Metabolism and Disposition: The Biological Fate of Chemicals 36(9):1794-1802.
182. Pawarode, A., et al. (2007). Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemotherapy and Pharmacology 60(2):179-188.
183. Qadir, M., et al. (2005). Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clinical Cancer Research 11(6):2320-2326.
184. de Bruin, M., et al. (1999). Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Letters 146(2):117-126.
185. Allen, J.D., et al. (2002). Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Molecular Cancer Therapeutics 1(6):417- 425.
186. Gekeler, V., et al. (1995). The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochemical and Biophysical Research Communications 208(1):345-352.
187. L eier, I., et al. (1994). The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. The Journal of Biological Chemistry 269(45):27807-27810.
188. Brand, W., et al. (2010). The effect of co-administered flavonoids on the metabolism of hesperetin and the disposition of its metabolites in Caco-2 cell monolayers. Molecular Nutrition & Food Research 54(6):851-860.
189. Yoshikawa, M., et al. (2004). Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. Journal of Experimental Therapeutics and Oncology 4(1):25-35.
190. K atayama, K., et al. (2007). Flavonoids inhibit breast cancer resistance proteinmediated drug resistance: Transporter specificity and structure-activity relationship. Cancer Chemotherapy and Pharmacology 60(6):789-797.
191. L ohner, K., et al. (2007). Flavonoids alter P-gp expression in intestinal epithelial cells in vitro and in vivo. Molecular Nutrition & Food Research 51(3):293-300.
192. Sugatani, J., et al. (2004). The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochemical Pharmacology 67(5):989-1000.
193. Bock, K.W., et al. (2000). Coordinate induction by antioxidants of UDPglucuronosyltransferase UGT1A6 and the apical conjugate export pump MRP2 (multidrug resistance protein 2) in Caco-2 cells. Biochemical Pharmacology 59(5): 467-470.
194. V ernhet, L., et al. (2001). Arsenic induces expression of the multidrug resistanceassociated protein 2 (MRP2) gene in primary rat and human hepatocytes. The Journal of Pharmacology and Experimental Therapeutics 298(1):234-239.
195. Ebert, B., Seidel, A., Lampen, A. (2007). Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene- 3-sulfate. Toxicological Sciences 96(2):227-236.
196. El-Sheikh, A.A., Masereeuw, R., Russel, F.G. (2008). Mechanisms of renal anionic drug transport. European Journal of Pharmacology 585(2-3):245-255.
197. Shitara, Y., Sato, H., Sugiyama, Y. (2005). Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annual Review of Pharmacology and Toxicology 45:689-723.
198. U eo, H., et al. (2005). Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochemical Pharmacology 70(7):1104-1113.
199. Ho, E.S., et al. (2000). Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. Journal of the American Society of Nephrology 11(3):383-393.
200. Whitley, A.C., Sweet, D.H., Walle, T. (2005). The dietary polyphenol ellagic acid is a potent inhibitor of hOAT1. Drug Metabolism and Disposition: The Biological Fate of Chemicals 33(8):1097-1100.
201. Hong, S.S., et al. (2007). Interaction characteristics of flavonoids with human organic anion transporter 1 (hOAT1) and 3 (hOAT3). Pharmacological Research 56(6):468-473.
202. Jang, E.H., et al. (2005). Effects of green tea extract administration on the pharmacokinetics of clozapine in rats. The Journal of Pharmacy and Pharmacology 57(3):311-316.
203. Quintieri, L., et al. (2011). Inhibition of cytochrome P450 2C8-mediated drug metabolism by the flavonoid diosmetin. Drug Metabolism and Pharmacokinetics 26(6):559-568.
204. Sun, D.X., et al. (2010). Reversible inhibition of three important human liver cytochrome p450 enzymes by tiliroside. Phytotherapy Research 24(11): 1670-1675.
205. von Moltke, L.L., et al. (2004). Inhibition of human cytochromes P450 by components of Ginkgo biloba. The Journal of Pharmacy and Pharmacology 56(8): 1039-1044.
206. Miniscalco, A., Lundahl, J., Regardh, C.G., Edgar, B., Eriksson, U.G. (1992). Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. The Journal of Pharmacology and Experimental Therapeutics 261(3):1195-1199.
207. van der Logt, E.M., Roelofs, H.M., Nagengast, F.M., Peters, W.H. (2003). Induction of rat hepatic and intestinal UDP-glucuronosyltransferases by naturally occurring dietary anticarcinogens. Carcinogenesis 24(10):1651-1656.
208. Williams, J.A., et al. (2002). Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metabolism and Disposition: The Biological Fate of Chemicals 30(11): 1266-1273.
209. De Santi, C., Pietrabissa, A., Spisni, R., Mosca, F., Pacifici, G.M. (2000). Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica; The Fate of Foreign Compounds in Biological Systems 30(9):857-866.
210. Harris, R.M., et al. (2004). Phytoestrogens are potent inhibitors of estrogen sulfation: Implications for breast cancer risk and treatment. The Journal of Clinical Endocrinology and Metabolism 89(4):1779-1787.
211. Petri, N., et al. (2003). Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metabolism and Disposition: The Biological Fate of Chemicals 31(6):805-813.
212. Mizoyama, Y., Takaki, H., Sugihara, N., Furuno, K. (2004). Inhibitory effect of flavonoids on N-acetylation of 5-aminosalicylic acid in cultured rat hepatocytes. Biological & Pharmaceutical Bulletin 27(9):1455-1458.
213. C ritchfield, J.W., Welsh, C.J., Phang, J.M., Yeh, G.C. (1994). Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochemical Pharmacology 48(7): 1437-1445.
214. Wang, X., Wolkoff, A.W., Morris, M.E. (2005). Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metabolism and Disposition: The Biological Fate of Chemicals 33(11): 1666-1672.
215. Song, J., et al. (2002). Flavonoid inhibition of sodium-dependent vitamin C transporter 1 (SVCT1) and glucose transporter isoform 2 (GLUT2), intestinal transporters for vitamin C and Glucose. The Journal of Biological Chemistry 277(18): 15252-15260.
216. Yu, Z., Fong, W.P., Cheng, C.H. (2007). Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells. Drug Metabolism and Disposition: The Biological Fate of Chemicals 35(6):981-986.
217. Shim, C.K., Cheon, E.P., Kang, K.W., Seo, K.S., Han, H.K. (2007). Inhibition effect of flavonoids on monocarboxylate transporter 1 (MCT1) in Caco-2 cells. The Journal of Pharmacy and Pharmacology 59(11):1515-1519.
218. K won, O., et al. (2007). Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. The FASEB Journal 21(2):366-377.
219. L e Bail, J.C., Champavier, Y., Chulia, A.J., Habrioux, G. (2000). Effects of phytoestrogens on aromatase, 3beta and 17beta-hydroxysteroid dehydrogenase activities and human breast cancer cells. Life Sciences 66(14):1281-1291.
220. Jang, S.I., et al. (2003). Hepatoprotective effect of baicalin, a major flavone from Scutellaria radix, on acetaminophen-induced liver injury in mice. Immunopharmacology and Immunotoxicology 25(4):585-594.
221. C anivenc-Lavier, M.C., Vernevaut, M.F., Totis, M., Siess, M.H., Magdalou, J., Suschetet, M. (1996). Comparative effects of flavonoids and model inducers on drugmetabolizing enzymes in rat liver. Toxicology 114(1):19-27.
222. Obermeier, M.T., White, R.E., Yang, C.S. (1995). Effects of bioflavonoids on hepatic P450 activities. Xenobiotica; The Fate of Foreign Compounds in Biological Systems 25(6):575-584.
223. K ao, Y.C., Zhou, C., Sherman, M., Laughton, C.A., Chen, S. (1998). Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. Environmental Health Perspectives 106(2):85-92.
224. Sun, X.Y., Plouzek, C.A., Henry, J.P., Wang, T.T., Phang JM, Increased, U.D. (1998). P-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells. Cancer Research 58(11): 2379-2384.
225. Satoh, H., et al. (2005). Citrus juices inhibit the function of human organic aniontransporting polypeptide OATP-B. Drug Metabolism and Disposition: The Biological Fate of Chemicals 33(4):518-523.
226. Shih, H., Pickwell, G.V., Quattrochi, L.C. (2000). Differential effects of flavonoid compounds on tumor promoter-induced activation of the human CYP1A2 enhancer. Archives of Biochemistry and Biophysics 373(1):287-294.
227. C atterall, F., McArdle, N.J., Mitchell, L., Papayanni, A., Clifford, M.N., Ioannides, C. (2003). Hepatic and intestinal cytochrome P450 and conjugase activities in rats treated with black tea theafulvins and theaflavins. Food and Chemical Toxicology 41(8):1141-1147.
228. Muto, S., Fujita, K., Yamazaki, Y., Kamataki, T. (2001). Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. Mutation Research 479(1-2):197-206.
229. Isozaki, T., Tamura, H. (2001). Epigallocatechin gallate (EGCG) inhibits the sulfation of 1-naphthol in a human colon carcinoma cell line, Caco-2. Biological & Pharmaceutical Bulletin 24(9):1076-1078.
230. C oughtrie, M.W., Johnston, L.E. (2001). Interactions between dietary chemicals and human sulfotransferases-molecular mechanisms and clinical significance. Drug Metabolism and Disposition: The Biological Fate of Chemicals 29(4 Pt 2):522-528.
231. Maliakal, P.P., Wanwimolruk, S. (2001). Effect of herbal teas on hepatic drug metabolizing enzymes in rats. The Journal of Pharmacy and Pharmacology 53(10):1323-1329.
232. Maliakal, P.P., Coville, P.F., Wanwimolruk, S. (2001). Tea consumption modulates hepatic drug metabolizing enzymes in Wistar rats. The Journal of Pharmacy and Pharmacology 53(4):569-577.
233. Fuchikami, H., Satoh, H., Tsujimoto, M., Ohdo, S., Ohtani, H., Sawada, Y. (2006). Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metabolism and Disposition: The Biological Fate of Chemicals 34(4):577-582.
234. C hen, C.H., Hsu, H.J., Huang, Y.J., Lin, C.J. (2007). Interaction of flavonoids and intestinal facilitated glucose transporters. Planta Medica 73(4):348-354.
235. Dreiseitel, A., et al. (2009). Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1. British Journal of Pharmacology 158(8):1942-1950.
236. K itagawa, S. (2006). Inhibitory effects of polyphenols on p-glycoprotein-mediated transport. Biological & Pharmaceutical Bulletin 29(1):1-6.
237. Peng, W.X., Li, H.D., Zhou, H.H. (2003). Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers. European Journal of Clinical Pharmacology 59(3):237-241.
238. K ent, U.M., Aviram, M., Rosenblat, M., Hollenberg, P.F. (2002). The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metabolism and Disposition: The Biological Fate of Chemicals 30(6):709-715.
239. Helsby, N.A., Williams, J., Kerr, D., Gescher, A., Chipman, J.K. (1997). The isoflavones equol and genistein do not induce xenobiotic-metabolizing enzymes in mouse and in human cells. Xenobiotica; The Fate of Foreign Compounds in Biological Systems 27(6):587-596.
240. Appelt, L.C., Reicks, M.M. (1999). Soy induces phase II enzymes but does not inhibit dimethylbenz[a]anthracene-induced carcinogenesis in female rats. The Journal of Nutrition 129(10):1820-1826.
241. Zhang, S., Morris, M.E. (2003). Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharmaceutical Research 20(8):1184-1191.
242. Dupuy, J., Larrieu, G., Sutra, J.F., Lespine, A., Alvinerie, M. (2003). Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: Quercetin. Veterinary Parasitology 112(4):337-347.